Cytokinetics ALS drug wins ‘orphan’ status in Europe

Via Scoop.it – ALS Lou Gehrig’s Disease
European regulators granted “orphan” status to a potential treatment for Lou Gehrig’s disease developed by South San Francisco’s Cytokinetics Inc. CK-2017357, which already has orphan drug designation in the United States, activates a muscle protein, called troponin, that could improve ALS patients’ ability to breathe as well as walk.
Via www.bizjournals.com